Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...
Moderna says its long-running patent dispute with Pfizer and BioNTech isn't over even after a decision by an administrative ...
Investor's Business Daily on MSN6h
Is Moderna Stock A Sell As RFK Jr. Reportedly Mulls A Massive Funding Pull?Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine. Is MRNA stock ...
Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...
As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...
The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.
It has been five years since the World Health Organisation (WHO) declared COVID-19 a pandemic in March 2020 a decision that ...
The Patent Trial and Appeal Board agreed with Pfizer and its German partner that Moderna's patents were invalid based on "prior art" that disclosed the inventions before Moderna patented them. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback